Brain serotonin transporter binding in non-depressed patients with Parkinson's disease

European Journal of Neurology

Volumn 14, Issue 5, 2007, Pages 523-528

  Guttman, M ^b,c   Boileau, I ^b   Warsh, J ^b   Saint Cyr, J A ^d   Ginovart, N ^b   McCluskey, T ^b   Houle, S ^b   Wilson, A ^b   Mundo, E ^e   Rusjan, P ^b   Meyer, J ^b   Kish, S J ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Centre for Movement Disorders   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

Depression; Parkinson's disease; Serotonin; Serotonin transporter

Indexed keywords

BENZONITRILE; BIOLOGICAL MARKER; RADIOLIGAND; SEROTONIN TRANSPORTER;

ADULT; AGED; ARTICLE; BRAIN CORTEX; BRAIN REGION; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; INNERVATION; LIGAND BINDING; MAJOR DEPRESSION; MALE; MESENCEPHALON; MOLECULAR IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN BINDING; PUTAMEN; SEROTONINERGIC NERVE CELL; SEROTONINERGIC SYSTEM; STATISTICAL SIGNIFICANCE; STRUCTURED INTERVIEW;

AGED; BENZYLAMINES; BINDING, COMPETITIVE; BIOLOGICAL MARKERS; BRAIN; BRAIN CHEMISTRY; CARBON RADIOISOTOPES; DEPRESSIVE DISORDER; DOWN-REGULATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SYNAPTIC TRANSMISSION;

EID: 34247105301     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2007.01727.x     Document Type: Article

References (24)

1. Bernheimer H, Birkmayer W, Hornykiewicz O. Verteilung des 5-Hydroxytryptamins (Serotonin) im Gehirn des Menschen und sein Verhalten bei Patientin mit Parkinson-Syndrom. Klinische Wochenschrift 1961; 39: 1056-1059.
2. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. European Journal of Neurology 2006; 13: 1186-1202.
3. Kish SJ. Biochemistry of Parkinson's disease: is a brain serotonergic deficiency a characteristic of idiopathic Parkinson's disease? Advances in Neurology 2003; 91: 39-49.
4. Kerenyi L, Ricaurte GA, Schretlen DJ, et al. Positron emission tomography of striatal serotonin transporters in Parkinson disease. Archives of Neurology 2003; 60: 1223-1229.
5. Houle S, Ginovart N, Hussey D, Meyer JH, Wilson AA. Imaging the serotonin transporter with positron emission tomography: initial human studies with [11C]DAPP and [11C]DASB. European Journal of Nuclear Medicine 2000; 27: 1719-1722.
6. Mundo E, Walker M, Cate T, Macciardi F, Kennedy JL. The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings. Archives of General Psychiatry 2001; 58: 539-544.
7. Wilson AA, Ginovart N, Schmidt M, Meyer JH, Threkleld PG, Houle S. Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of (11)C-labeled 2-(phenylthio)araalkylamines. Journal of Medicinal Chemistry 2000; 43: 3103-3110.
8. Meyer JH, Wilson AA, Ginovart N, et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. American Journal of Psychiatry 2001; 158: 1843-1849.
9. 11C]-DASB binding to the human serotonin transporter: modeling strategies. Journal of Cerebral Blood Flow and Metabolism 2001; 21: 1342-1353.
10. Meyer JH, Houle S, Sagrati S, et al. Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Archives of General Psychiatry 2004; 61: 1271-1279.
11. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. Journal of Cerebral Blood Flow and Metabolism 1996; 16: 834-840.
12. Burger C, Buck A. Requirements and implementation of a flexible kinetic modeling tool. Journal of Nuclear Medicine 1997; 38: 1818-1823.
13. Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. American Journal of Psychiatry 2004; 161: 826-835.
14. Praschak-Rieder N, Wilson AA, Hussey DH, et al. Effects of tryptophan depletion upon the serotonin transporter in healthy humans. Biological Psychiatry 2005; 58: 825-830.
15. Kish SJ, Furukawa Y, Chang LJ, et al. Regional distribution of serotonin transporter protein in postmortem human brain. Is the cerebellum a SERT-free brain region? Nuclear Medicine and Biology 2005; 32: 123-128.
16. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Annals of Neurology 1984; 15: 217-227.
17. Rabiner EA, Gunn RN, Castro ME, et al. Beta-blocker binding to human 5-HT(1A) receptors in vivo and in vitro: implications for antidepressant therapy. Neuropsychopharmacology 2000; 23: 285-293.
18. Muller-Gartner HW, Links JM, Prince JL, et al. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. Journal of Cerebral Blood Flow and Metabolism 1992; 12: 571-583.
19. Kvernmo T, Hartter S, Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clinical Therapeutics 2006; 28: 1065-1078.
20. Talbot PS, Frankle WG, Hwang DR, et al. Effects of reduced endogenous 5-HT on the in vivo binding of the serotonin transporter radioligand 11C-DASB in healthy humans. Synapse 2005; 55: 164-175.
21. Chinaglia G, Landwehrmeyer B, Probst A, Palacios JM. Serotonergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study with [3H]citalopram. Neuroscience 1993; 54: 691-699.
22. 11C]RTI-32 PET studies of the dopamine transporter in early dopanaïve Parkinson's disease: implications for the symptomatic threshold. Neurology 1997; 48: 1578-1583.
23. 11C](+)McN5652. Biological Psychiatry 2002; 51: 715-722.
24. Meyer JH. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. Journal of Psychiatry and Neuroscience 2007; 32: 86-102.